<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9665">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00731198</url>
  </required_header>
  <id_info>
    <org_study_id>Changhai-080615</org_study_id>
    <nct_id>NCT00731198</nct_id>
  </id_info>
  <brief_title>Drotaverine Hydrochloride Versus Hyoscine-N-butylbromide for Duodenal Antimotility During Endoscopic Retrograde Cholangiopancreatography (ERCP)</brief_title>
  <official_title>Drotaverine Hydrochloride Versus Hyoscine-N-butylbromide for Duodenal Antimotility During ERCP: a Prospective, Multicenter Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Changhai Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Changhai Hospital</source>
  <oversight_info>
    <authority>China: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the present study was to evaluate the use of drotaverine hydrochloride versus
      hyoscine-N-butylbromide in reducing duodenal motility during diagnostic and therapeutic
      ERCP.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      ERCP is an important endoscopic technique in the diagnosis and treatment of pancreatic and
      biliary diseases. Duodenal peristalsis can make cannulation of the papilla and the necessary
      therapeutic procedures difficult. Intravenous hyoscine-N-butylbromide is often used during
      ERCP to inhibit duodenal motility and enhance cannulation in China. However, the
      pharmaceutical agent is occasionally associated with serious complications such as
      cardiovascular events or anaphylactic shock. Hyoscine-N-butylbromide may also affect the
      ocular, urinary, and salivary systems.

      Drotaverine hydrochloride is an analogue of papaverine with smooth muscle relaxant
      properties. It is a non-anticholinergic antispasmodic, which selectively inhibits
      phosphodiesterase IV and is accompanied by a mild calcium channel-blocking effect. Adverse
      effects with drotaverine hydrochloride, such as hypotension, vertigo, nausea, and
      palpitation, are mostly mild. It can be supposed that intravenous drotaverine hydrochloride
      might be a feasible antimotility alternative to intravenous hyoscine-N-butylbromide in ERCP.
      But there is no clear evidence to recommend the use of drotaverine hydrochloride as an
      antispasmodic during ERCP.

      The aim of the present study was to evaluate the use of drotaverine hydrochloride versus
      hyoscine-N-butylbromide in reducing duodenal motility during diagnostic and therapeutic
      ERCP. The effects of drotaverine hydrochloride on facilitative cannulation and its adverse
      effects were also compared to hyoscine-N-butylbromide.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>The Grades of the Number of Duodenal Contractions</measure>
    <time_frame>Intra-procedure</time_frame>
    <safety_issue>No</safety_issue>
    <description>a duodenal motility grade was determined as follows: 0 = no motility; 1 = less than five contractions/minute; 2 = 5 to 10/minute; 3 = 11 to 15/minute; 4 = continuous.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cannulation Time</measure>
    <time_frame>Intra-procedure</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Successful Selective Cannulation</measure>
    <time_frame>Intra-procedure</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Post-ERCP Complications</measure>
    <time_frame>48 hours after ERCP</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side Effects</measure>
    <time_frame>Intra-procedure and 24 hours after ERCP</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">650</enrollment>
  <condition>ERCP</condition>
  <condition>Pancreatic Diseases</condition>
  <condition>Bile Duct Diseases</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drotaverine hydrochloride</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Hyoscine-N-butylbromide</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Drotaverine hydrochloride</intervention_name>
    <description>Drotaverine hydrochloride 40mg was administered intravenously 15 minutes before ERCP</description>
    <arm_group_label>1</arm_group_label>
    <other_name>No-spa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hyoscine-N-butylbromide</intervention_name>
    <description>Hyoscine-N-butylbromide 20mg was administered intravenously 15 minutes before ERCP.</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Scopolamine Butylbromide</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients undergoing ERCP above the age of 18 years

        Exclusion Criteria:

          -  Patient with Billroth II gastrectomy

          -  Known previous sphincterotomy

          -  Active acute pancreatitis before ERCP

          -  Ongoing acute cholangitis before ERCP

          -  Hypotension (systolic blood pressure &lt; 100 mmHg)

          -  Second-degree and third-degree atrioventricular block

          -  Heart failure

          -  Glaucoma

          -  Obstructive uropathy

          -  Impaired renal function (serum creatinine &gt; 133Î¼mol/L)

          -  Pregnant or breastfeeding women
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhaoshen Li, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Changhai Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fujian Provincial Hospital</name>
      <address>
        <city>Fuzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First People's Hospital of Hangzhou</name>
      <address>
        <city>Hangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heilongjiang Provincial Hospital</name>
      <address>
        <city>Harbin</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Changhai Hospital, Second Military Medical University</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2009</verification_date>
  <lastchanged_date>August 31, 2010</lastchanged_date>
  <firstreceived_date>August 6, 2008</firstreceived_date>
  <firstreceived_results_date>September 14, 2009</firstreceived_results_date>
  <responsible_party>
    <name_title>Zhaoshen Li</name_title>
    <organization>Changhai Hospital, Second Military Medical University</organization>
  </responsible_party>
  <keyword>ERCP</keyword>
  <keyword>Drotaverine hydrochloride</keyword>
  <keyword>Hyoscine-N-butylbromide</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bile Duct Diseases</mesh_term>
    <mesh_term>Pancreatic Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Butylscopolammonium Bromide</mesh_term>
    <mesh_term>Drotaverin</mesh_term>
    <mesh_term>Papaverine</mesh_term>
    <mesh_term>Scopolamine Hydrobromide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Experimental</title>
          <description>Drotaverine hydrochloride</description>
        </group>
        <group group_id="P2">
          <title>Active Comparator</title>
          <description>Hyoscine-N-butylbromide</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="325"/>
                <participants group_id="P2" count="325"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="319"/>
                <participants group_id="P2" count="319"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Experimental</title>
          <description>Drotaverine hydrochloride</description>
        </group>
        <group group_id="B2">
          <title>Active Comparator</title>
          <description>Hyoscine-N-butylbromide</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="325"/>
                <measurement group_id="B2" value="325"/>
                <measurement group_id="B3" value="650"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="205"/>
                <measurement group_id="B2" value="197"/>
                <measurement group_id="B3" value="402"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="120"/>
                <measurement group_id="B2" value="128"/>
                <measurement group_id="B3" value="248"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="56.98" spread="15.75"/>
                <measurement group_id="B2" value="59.20" spread="16.14"/>
                <measurement group_id="B3" value="58.09" spread="15.97"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="139"/>
                <measurement group_id="B2" value="173"/>
                <measurement group_id="B3" value="312"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="186"/>
                <measurement group_id="B2" value="152"/>
                <measurement group_id="B3" value="338"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>China</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="325"/>
                <measurement group_id="B2" value="325"/>
                <measurement group_id="B3" value="650"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Grades of the Number of Duodenal Contractions</title>
        <description>a duodenal motility grade was determined as follows: 0 = no motility; 1 = less than five contractions/minute; 2 = 5 to 10/minute; 3 = 11 to 15/minute; 4 = continuous.</description>
        <time_frame>Intra-procedure</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Experimental</title>
            <description>Drotaverine hydrochloride</description>
          </group>
          <group group_id="O2">
            <title>Active Comparator</title>
            <description>Hyoscine-N-butylbromide</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="319"/>
                  <measurement group_id="O2" value="319"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>The Grades of the Number of Duodenal Contractions</title>
            <description>a duodenal motility grade was determined as follows: 0 = no motility; 1 = less than five contractions/minute; 2 = 5 to 10/minute; 3 = 11 to 15/minute; 4 = continuous.</description>
            <units>scores on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1.13" spread="0.89"/>
                  <measurement group_id="O2" value="1.17" spread="0.82"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cannulation Time</title>
        <time_frame>Intra-procedure</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Successful Selective Cannulation</title>
        <time_frame>Intra-procedure</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of Post-ERCP Complications</title>
        <time_frame>48 hours after ERCP</time_frame>
        <safety_issue>Yes</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Side Effects</title>
        <time_frame>Intra-procedure and 24 hours after ERCP</time_frame>
        <safety_issue>Yes</safety_issue>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Experimental</title>
          <description>Drotaverine hydrochloride</description>
        </group>
        <group group_id="E2">
          <title>Active Comparator</title>
          <description>Hyoscine-N-butylbromide</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="319"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="319"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Zhaoshen Li M.D.</name_or_title>
      <organization>Changhai Hospital, Second Military Medical University, Shanghai, China</organization>
      <phone>86-21-81873271</phone>
      <email>zhaoshenlismmu@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
